Vasopressin injection - Par Pharmaceutical Companies
Alternative Names: VasostrictLatest Information Update: 16 Jan 2022
Price :
$50 *
At a glance
- Originator Par Pharmaceutical Companies
- Class Antidiuretics; Antihaemorrhagics; Basic amino acids; Diamino amino acids; Hormones; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypotension
Most Recent Events
- 01 Mar 2018 Par Pharmaceuticals received preliminary injunction preventing QuVa Pharma from marketing and releasing a planned vasopressin product that would compete with Vasostrict®
- 30 Oct 2017 Par Pharmaceuticals has patent protection for vasopressin injection in USA
- 28 Jun 2016 Par Pharmaceuticals has patent protection for vasopressin injection in USA